J&J is taking an immuno-oncology drug licensed in from Aduro and matching it with Bristol-Myers Squibb’s pioneering checkpoint drug Opdivo in the latest example of the tsunami of I/O combo studies taking shape off the coast of the global R&D industry. The move comes one day after Bristol-Myers $BMY tapped a veteran player to take the head of its rapidly growing oncology development operations.
J&J $JNJ—a major player which has struck a string of prominent cancer deals in the past few years—was drawn to the therapeutic because of its use of engineered Live Attenuated Double-Deleted (LADD) Listeria monocytogenes to spur an immune response against tumors. LADD is used to induce presentation of an antigen. And the new partners are tackling non-small cell lung cancer in an early-stage study, probably designed for a quick ramp-up into a pivotal trial if they get the desired results.
Aduro used the same LADD tech to design its top drug, CRS-207.
Yesterday, Bristol-Myers also noted a key change in senior R&D execs. Michael Giordano, a 17-year veteran at Bristol-Myers, has now “retired,” and Fouad Namouni has taken over oncology development, with responsibility covering everything from early stage development through to commercialization.
It’s a plum post. Bristol-Myers has reshaped its R&D effort in recent years to position the company as a major player in the lucrative oncology field. Company execs positioned Opdivo as the lead checkpoint drug on the market, and they’ve been pouring resources into the division.
The expansion includes a long lineup of these combo studies.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.Free Subscription